Psoriasis
Shorts
0:41
Advancing Patient Care Through Shared Medical Expertise
4 days ago
by
Douglas DiRuggiero, DMSc, MHS, PA-C
0:40
Why Psoriasis is More Than Just a Skin Disease
2 months ago
by
Amanda Caldwell, MSN, APRN-C
0:24
Personalized Treatment: How to Choose the Best Option
2 months ago
by
Amanda Caldwell, MSN, APRN-C
0:41
Why 'Age' Changes Everything In Medicine
2 months ago
by
Daniel C. Butler, MD
Continuing Medical Education
All News
Advertisement
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Review common questions about psoriasis, including systemic disease, PsA screening, treatment selection, triggers, and patient counseling.
Long-term envudeucitinib data showed increasing skin clearance through 48 weeks, with 54% of continuously treated patients achieving PASI 100.
Test your knowledge of GPP recognition, clinical presentation, complications, and targeted treatment!
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Advertisement
New phase 3 data presented at the AAD Innovation Academy show zasocitinib achieved high rates of clear or almost clear skin at the scalp, palms, soles, and nails at week 16.
Hormonal shifts shape psoriasis and atopic dermatitis through puberty, pregnancy, postpartum, and menopause, guiding safer treatment choices and protecting pregnancy outcomes.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.
Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.
At EULAR 2026, investigators presented head-to-head data demonstrating significantly higher joint response rates with bimekizumab compared with risankizumab in PsA.
Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.
Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.
Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.
New top-line results from the BE BOLD trial provide dermatology clinicians with comparative data on 2 biologic therapies targeting different inflammatory pathways in psoriatic arthritis (PsA).
Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.
Real-world data show IL-17 biologics rapidly improve special-site psoriasis and quality of life, as researchers identified predictors of PASI75/90 response.
New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
4
Improving Early Identification and Escalation of HS
5